SCHEMBL6417007

SCHEMBL6417007

Fc1ccc(Nc2nc3nonc3nc2NN=Cc2ccco2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.51
TDP1 Q9NUW8 5/20 0.51
ALDH1A1 P00352 3/20 0.51
NPSR1 Q6W5P4 2/20 0.51
LMNA P02545 2/20 0.51
HTT P42858 1/20 0.51
SMN1; SMN2 Q16637 9/20 0.48
TP53 P04637 2/20 0.48
PKM P14618 1/20 0.44
NPC1 O15118 4/20 0.42
RAB9A P51151 4/20 0.42
KMT2A Q03164 8/20 0.41
MEN1 O00255 7/20 0.41
GAA P10253 5/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
KDM4E B2RXH2 2/20 0.40
NFKB1 P19838 2/20 0.40
NFKB2 Q00653 2/20 0.40
RELA Q04206 2/20 0.40
MAOB P27338 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6417000 1.00 MAPT (0.51) MAPTTDP1ALDH1A1NPSR1LMNA
SCHEMBL3055383 0.90 GAA (0.49) MAPTTDP1ALDH1A1NPSR1LMNA
SCHEMBL6421048 0.90 GAA (0.49) MAPTTDP1ALDH1A1NPSR1LMNA
SCHEMBL6508259 0.89 MAPT (0.48) MAPTTDP1ALDH1A1NPSR1LMNA
SCHEMBL6420784 0.89 MAPT (0.48) MAPTTDP1ALDH1A1NPSR1LMNA
SCHEMBL6419657 0.85 SMN1; SMN2 (0.50) MAPTTDP1ALDH1A1NPSR1LMNA
SCHEMBL6419646 0.85 SMN1; SMN2 (0.50) MAPTTDP1ALDH1A1NPSR1LMNA
SCHEMBL6414713 0.84 SMN1; SMN2 (0.50) MAPTTDP1ALDH1A1LMNAHTT
SCHEMBL3058317 0.81 SMN1; SMN2 (0.48) MAPTTDP1ALDH1A1NPSR1LMNA
SCHEMBL6431993 0.81 SMN1; SMN2 (0.51) MAPTTDP1ALDH1A1NPSR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 MAPT 4420/4885TDP1 4777/4885ALDH1A1 1119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.